Interleukin 17a Protein

Catalog No. ABIN7318648

This Recombinant Interleukin 17a protein is expressed in Escherichia coli (E. coli).

Quick Overview for Interleukin 17a Protein (ABIN7318648)

Target: Interleukin 17a (IL17A) (Interleukin 17A (IL17A))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Purity: > 95 % as determined by reducing SDS-PAGE.

Product Details

Purpose: Recombinant Human Interleukin-17A/IL-17A Protein (Active)

Sequence: Ile20-Ala155

Characteristics: Recombinant Human Interleukin-17A is produced by our E.coli expression system and the target gene encoding Ile20-Ala155 is expressed.

Endotoxin Level: < 1.0 EU per μg as determined by the LAL method.

Biological Activity Comment: Measured by its ability to induce IL-6 secretion by NIH-3T3 mouse embryonic fibroblast cells. The ED50 for this effect is 1-7 ng/ml.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from a 0.2 μm filtered solution of 20 mM PB, pH 7.4.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Target Details

Target: Interleukin 17a (IL17A) (Interleukin 17A (IL17A))

Alternative Name: Interleukin-17A/IL-17A

Background:

Background: Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

Synonym: Interleukin-17A, IL-17, IL-17A, Cytotoxic T-Lymphocyte-Associated Antigen 8, CTLA-8, IL17A, CTLA8, IL17

Molecular Weight: 15.3 kDa

UniProt: Q16552